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Nonalcoholic fatty liver disease (NAFLD) is the hepaticmanifestation ofmetabolic syndrome
and a serious health burden worldwide which increases risk of cirrhosis, type 2 diabetes
mellitus (T2DM), and cardiovascular complications. Current epidemics of obesity, unhealthy
dietary patterns, and sedentary lifestyles, all contribute to the high prevalence of NAFLD.
Dietary patterns and nutrients are important contributors to the development, progres-
sion, and treatment of NAFLD. A healthy diet is beneﬁcial for all NAFLD patients beyond
weight reduction. Generally, hypercaloric diets, especially rich in trans/saturated fat and
cholesterol, high consumption of red and processed meat, and fructose-sweetened bever-
ages seem to increase the risk of progression toward nonalcoholic steatohepatitis (NASH),
whereas reducing caloric intake and high-glycemic index (GI) foods, increasing consump-
tion ofmonounsaturated fatty acids, omega-3 fatty acids, ﬁbers, and speciﬁc protein sources
such as ﬁsh and poultry have preventive and therapeutic effects. Therefore, nutrition serves
as a major route of prevention and treatment of NAFLD, and patients with NAFLD shouldhave an individualized diet recommendation. In this review, the evidence linking macronu-
trients to NAFLD are discussed.
© 2014 Korea Institute of Oriental Medicine. Published by Elsevier. This is an open access
As pharmacotherapy is not effective and safe enough,1. Introduction
Nonalcoholic fatty liver disease (NAFLD) is a metabolic stress-
related liver disease deﬁned as the hepatic accumulation of
lipids, mainly triglyceride, in the absence of substantial alco-
hol consumption (< 20 g/day) or other secondary causes. It
encompasses a spectrum ranging from simple steatosis to
nonalcoholic steatohepatitis (NASH), which increases the risk
of cirrhosis and hepatocellular carcinoma. Currently, NAFLD is
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the main cause of chronic liver disease worldwide. Its preva-
lence is much higher in diabetic or obese individuals. Patients
withNAFLDshould be treated for steatohepatitis and the asso-
ciated metabolic comorbidities, whereas patients with simple
steatosis only need to treat the associated conditions to pre-
vent hepatic and metabolic complications.1,2of Medicine, Yonsei University, 20 Ilsan-ro, Wonju, Gangwondo
and obesity is intimately associated with hepatic steatosis,
lifestyle modiﬁcation is the ﬁrst line of treatment. The usual
steps for the management of NAFLD are gradual weight loss,
vier. This is an open access article under the CC BY-NC-ND license
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dopting a healthy diet which has beneﬁts beyond weight
eduction, and increased physical activity. Several studies
ave demonstrated the beneﬁcial impacts of dietary interven-
ions in treating obesity, insulin resistance, and NAFLD and
hat speciﬁc macronutrients might beneﬁt NAFLD indepen-
ent of weight loss.3–8 This review summarizes the evidence
or the macronutrient effects including carbohydrates, lipids,
nd proteins in the management of patients with NAFLD.
. Macronutrient effects on NAFLD
arbohydrates
arbohydrates (CHO) are the main source of body energy for
oth children and adults. Based on the level of polymerization,
hey are categorized as sugars (monosaccharides and dis-
ccharides), oligosaccharides, and polysaccharides. Although
tudies have shown that several carbohydrates may be linked
o NAFLD, the main focus has been on glycemic index, fruc-
ose, and ﬁber.9
Several studies suggest that CHO restriction can improve
nsulin resistance through reducing glycemic load and beta-
ell insulin secretion.10 Low-CHO diets could also reduce
erum triglycerides, insulin, and glucose and increase high-
ensity lipoprotein (HDL).11 Concerning NAFLD, a recent
ross-sectional study showed a positive correlation between
minotransferase levels (a surrogate measure of NAFLD at
opulation level) and CHO intake after adjusting for age, body
ass index (BMI), and energy intake.12 In another report, a post
oc analysis showed that of 52 obese insulin-resistant patients
ubjected to a hypocaloric diet based on a low-CHO/high-fat
iet (40% and 45% total calories per day, respectively) or a
igh-CHO/low-fat diet (60% and 25%, respectively), reduction
f alanine transaminase (ALT) and serum insulin was signiﬁ-
antly greater in the patients allocated to the low CHO diet.13
imilarly, a randomized study of 22 obese patients compar-
ng a low-CHO (< 50g/day) versus a high-CHO (> 180g/day)
ypocaloric diet, showed a greater reduction of liver glucose
roduction and hepatic steatosis at 48hours in patients on the
ow-CHO diet. Nonetheless, the differences in liver steatosis
ere insigniﬁcant after achieving > 7% weight loss, irrespec-
ive of the CHO composition of the diet.14 This data propose
hat in spite of an early weight-independent effect of low-CHO
iets on liver steatosis and insulin resistance, this effect is sur-
assedby signiﬁcantweight loss. Congruentwith this, another
andomized study of 170 obese or overweight patients com-
aring a hypocaloric low-CHO diet (> 1200 calories restriction
er day, < 90 g CHO per day, and > 30% calories per day from
at) versus a hypocaloric low-fat diet (< 20% of total calorie
ntake), showed a similar reduction in weight (7.4%), fat mass,
isceral adipose mass, insulin resistance, and liver fat after
6-month follow-up.15 Histology assessments were not pro-
ided by any of these studies. Therefore, although moderate
HO restriction seems to have no further effect on liver steato-
is in patients with signiﬁcant weight loss (≥ 7%), its impact
n liver inﬂammation and ﬁbrosis and its utility in patients
ithout signiﬁcant weight loss have not yet been elucidated.
Glycemic load is deﬁned as the absolute amount of glu-
ose in grams that is provided by the food group concerned.
igh-glycemic-load foods (including those rich in simple and193
complex carbohydrates, such as chocolates, candies, cook-
ies, or potato, pasta, bread, and rice) increase postprandial
glycemia and insulinemia, especially in patients with insulin
resistance.16 Glycemic index (GI) is deﬁned as the propor-
tion of food converted and absorbed as glucose, and it is
expressed as a percentage. A recent meta-analysis of stud-
ies on dietary regimens based on GI, concluded that higher
glucose and insulin exposure is associated with long-term
complications, such as type 2 diabetes mellitus (T2DM) and
cardiovascular disease (CVD).17,18 Likewise, a Cochrane meta-
analysis of six trials with a follow-up time between 1 month
and 6 months concluded that a diet based on low-GI prod-
ucts induces a signiﬁcantly higherweight loss (−1.1 kg) and fat
mass reduction.19 In a cross-sectional analysis of 257 healthy
individuals, Valtuen˜a et al20 demonstrated that there is an
association between high-GI food intake and the presence of
liver steatosis (assessed by ultrasound). However, longitudinal
prospective studies are needed to explore the effects of such
diets on NAFLD and hepatic inﬂammation.
During the past decades, fructose intake has consider-
ably increased. It is mainly derived from sucrose (table sugar)
and corn syrup which is abundantly used in sugar-sweetened
beverages.21 Fructose metabolism increases lipogenesis, free
radical oxygen species production, gut permeability, bacterial
overgrowth, and serum lipopolysaccharide levels. Further-
more, it reduces lipid oxidation.9,22 In animal studies, some
of these mechanisms have been suggested to play a role in
NASH and insulin resistance pathogenesis.
Longitudinal epidemiologic data from an analysis of the
Framingham study database (n=6039) demonstrated that the
consumption of one or more soft drinks per day increases
risk of obesity and metabolic syndrome, including all of its
components (impaired fasting glucose, high blood pressure,
hypertriglyceridemia, and low HDL).23 Additionally, a cross-
sectional analysis of 427 patients with biopsy-proven NAFLD
demonstrated that intake of seven or more sugar-sweetened
drinks perweek is associatedwith signiﬁcantly higher ﬁbrosis,
inﬂammation, andhepatocyte ballooning after adjustment for
age, sex, BMI, and total calorie intake.24 Recently, a study of
47 overweight patients allocated to a daily intake of 1 L of
sugar-sweetened soft drinks per day for 6 months showed a
signiﬁcant increase in liver fat (150%), muscle fat (200%), vis-
ceral adipose tissue fat (25%), serum triglycerides (32.7%), and
cholesterol (11.4%).25 It is important to note that whether this
effect is speciﬁc for an excess intake of fructose or is only
a consequence of calorie excess, is still under debate. Meta-
analyses have not demonstrated signiﬁcant effects of high
fructose intake on weight,26 and increased fasting triglyce-
rides are only observed in normal individuals with a high
intake of fructose.27 A recent study of 55 healthy individ-
uals who were allocated either to a high-fructose (1.5 g/kg/day,
3.0 g/kg/day, or 4.0 g/kg/day, n=7, n=17, and n=11, respec-
tively), high-glucose (3 g/kg/day, n=10), or high-saturated fat
diet (30% of total calorie intake, n=10) showed a signiﬁcant
increase in liver steatosis [assessed by magnetic resonance
spectroscopy (MRS))] only in patients exposed to 3 g/kg/day
or more of fructose, and this was higher compared with the
glucose group (60%, p<0.05) and similar to the saturated-fat
exposed groups (90%, p= insigniﬁcant).28 Although a direct
role of fructose in human NAFLD pathogenesis remains to be
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elucidated, patients should be advised to restrict fructose-rich
food and beverages.
Fibers are mainly plant-derived carbohydrates which are
generally resistant to human digestion.29 Several beneﬁcial
metabolic effects have been attributed to ﬁber, includ-
ing increased satiety, increased incretin secretion, reduced
absorption rate of CHO and proteins, systemic antiinﬂam-
matory effect, improved glycemic control, and modulation
of gut microbiota.29–31 A meta-analysis proposed that whole-
grain intake could signiﬁcantly reduce the CVD and T2DM
risk.32 In spite of several studies providing evidence of the
association between ﬁber consumption and decreased risk
of metabolic syndrome and type 2 diabetes, limited research
has been done regarding dietary ﬁber and NAFLD. In a cross-
sectional study of 247 healthy adults, higher degrees of
steatosis (assessed by ultrasound) correlated with high GI
diets, but there was no association between ﬁber intake and
hepatic steatosis.33 In another study, NAFLD patients were
supplemented with 10g/day of soluble ﬁber for 3 months and
a beneﬁcial effect on body weight, insulin sensitivity, and
transaminase levels was found. No histology assessment was
available in this study.34 There are no other human studies
focusing on the potential link between ﬁber consumption and
NAFLD.
3. Fat
Increased fat intake and Western diets have been linked to
insulin resistance, impaired postprandial lipid metabolism,
and the development or progression of NAFLD.35 In contrast to
cardiovascular and metabolic diseases, there is little epidemi-
ological evidence that the type of dietary fat is associated with
fatty liver.36
Impacts of polyunsaturated fatty acids (PUFAs) on NAFLD
have been extensively studied. Omega 3 fatty acids (-3
FAs), particularly docosahexaenoic acid and eicosapentaenoic
acid, reduce liver steatosis by upregulation of peroxisome
proliferator-activated receptor , resulting in higher FA oxi-
dation and lower lipogenesis.37 Furthermore, -3 FAs have
potent antiinﬂammatory and insulin sensitizing effects.38 In
line with this, a cross-sectional analysis has reported that
patients with NAFLD have lower -3 FAs and -3/-6 FAs ratio
than the controls.39 In addition, epidemiologic studies suggest
that increased ﬁsh intake (major source of-3 FAs)may reduce
the risk of hepatocellular carcinoma and CVD.40,41 A recent
meta-analysis of nine intervention studies clearly showed that
patients who were supplemented with an average of 4 g/day of
-3 in the formof capsules or oil, had a signiﬁcant reduction in
liver steatosis (assessed by MRS or liver ultrasound). However,
liver function tests were not signiﬁcantly affected.42
Meta-analyses suggest that higher consumption of
monounsaturated FA (MUFA) is associated with higher HDL
and lower triglycerides and that it improves glycemic control
in diabetic patients. Oleic acid is the most prevalent MUFA
in the diet, and olive oil is one of its major sources (other
sources are nuts and avocado).43 In animal models, MUFAs
have shown a positive effect on fat distribution, favoring the
deposition of fat in adipose tissues rather than in the liver.44
Concerning this, a recent randomized study of 45 diabeticIntegr Med Res ( 2 0 1 4 ) 192–197
patients comparing a high-CHO/low-GI/high-ﬁber diet (CHO
52% of total calorie intake and 28g of ﬁber) with a high MUFA
diet (28% of total calorie intake) for 8 weeks, demonstrated
a signiﬁcantly greater reduction of steatosis in the high-
MUFA-diet group (27% vs. 5%, p<0.05).45 Notwithstanding
the promising data on PUFA and MUFA, further randomized
controlled trials assessing histology outcomes are needed
to conﬁrm the beneﬁcial effects of these interventions in
NAFLD.
Trans FAs and saturated FAs have been associated with
insulin resistance, elevated low-density lipoprotein (LDL),
decreased HDL, and higher cardiovascular risk46,47 which
suggest that they may be involved in NAFLD pathogene-
sis. However, little evidence is available for their impacts on
NAFLD. In a cross-sectional case control trial, Musso et al48
compared 7-day nutritional records of 25 patients with NASH
with those of the controls. Patients with NAFLD had a higher
consumption of saturated fat and cholesterol and a lower
intake of PUFA, ﬁber, and vitamins C and E. Animal models
have shown that receiving high fat (63.33% of total calories per
day), high-trans FA diet (28.5% of total calorie intake) increases
body weight, aminotransferase levels, serum FA, liver steato-
sis, lipogenesis, and inﬂammatory mediators.49
Analysis of lipid proﬁle has demonstrated that free choles-
terol is signiﬁcantly elevated in the livers of patients with
NASH. In line with this, a large epidemiologic study reported
an adverse role of dietary cholesterol on liver disease out-
comes, signiﬁcantly increasing the risk of cirrhosis and liver
cancer.50 In animal models, high-cholesterol diets (1–2% w/w)
have increased hepatocyte-free cholesterol accumulation in
mitochondria, resulting in glutathione depletion, increased
susceptibility to tumor necrosis factor (TNF)-mediated apo-
ptosis, macrophages recruitment, and liver ﬁbrosis.51 Thus,
considering their association with increased cardiovascular
risk, excessive consumption of saturated fats, trans FAs, and
cholesterol should be reduced in patients with NAFLD, espe-
cially in those with hypercholesterolemia.
4. Protein
A multicenter randomized study (n=773 overweight adults)
demonstrated that a fair increase in protein intake (15.4% of
total calorie intake) combined with a low-GI diet, is associ-
ated with improved weight-loss maintenance.52 This ﬁnding
may be associated with the satiating effect and increased
energy expenditure relating to protein metabolism. However,
long-term effects of this type of diet should be considered.
In two long-term follow-up cohorts (n=129,716 and 10–16
years of follow-up53; n=38,094 with 10 years of follow-up54),
higher consumption of animal-derived protein signiﬁcantly
increased the incidence of diabetes and cardiovascular mor-
tality, although this association was only signiﬁcant for
processed meat.55 Moreover, a further analysis of one of these
cohorts showed that nuts, low-fat dairy, ﬁsh, and poultry actu-
56ally reduce cardiovascular risk. Concisely, high-protein diets
can be an alternative for weight maintenance but one should
be cautious regarding the protein source, prioritizing ﬁsh,
poultry, nuts, and legume-derived protein.
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Table 1 – Recommended nutritional intervention for patients with NAFLD* 60,61
Dietary Recommendation Do Do not
1. Calories restriction (500–1000kcal/ddeﬁcit): low fat
(<30%) or low CHO (<40%)
2. If low-CHO diet is decided, use more PUFA, MUFA, and
proteins derived from ﬁsh, poultry, nuts, and legumes
3. If low-fat diet is decided, use more low–GI foods and
proteins derived from ﬁsh, poultry, nuts, and legumes
4. Reduce consumption of trans
FA (<1%), saturated fats (<7%), and cholesterol (<200mg/d)
5. Increase intake of cereal-derived non-soluble ﬁber
(wholegrain) (25 g/d)
•Vegetables (3–5 servings/d)
•Legumes (4 servings/wk)
•Fruits (2–4 servings/d)
•Whole grains (daily)
•Nuts (4 servings/wk)
•Olive oil
•Oily ﬁsh (tuna, salmon, and
sardines) (≈100-gr serving at least
2/wk)
•Low-fat dairy products
•Fast food (least possible)
•Empty calories (cakes, cookies, ice
cream, candies)
•Unprocessed red meats (>300 g/wk)
•Processed meats (>2/wk)
•Potato chips (least possible)
•Potatoes
•Sugar-sweetened beverages (least
possible)
•Salt
CHO: Carbohydrate; GI: Glycemic Index
∗ Adapted from US Department of Agriculture. Available at: www.choosemyplate.gov; and American Heart Association. Available at:
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. Practical approaches
he typical Western diet pattern which is abundant in red
eat, trans FAs, fructose-sweetened beverages, and high-GI
HO and is low in PUFA, MUFA, vegetable-derived proteins,
nd ﬁber provides a threatening mixture of nutrients for the
iver and for metabolic processes. Kechagias et al57 prop-
rly illustrated this point. They submitted 16 healthy young
atients to a high calorie, fast food-based diet (> 2 fast food-
ased meals per day) for 4 weeks which led to a signiﬁcant
ncrease in weight and ALT, and a doubling of the liver fat
ontent. Therefore, from the standpoint of effective manage-
ent ofNAFLD, the elements of thismarkedlyunbalanceddiet
hould be corrected and in line with this, leisure time phys-
cal activity should be increased. However, to address subtle
ietary abnormalities in patients’ diets, every patient should
et an individualized diet recommendation with adequate
upport.
Food-oriented nutritional recommendations are highly
roﬁtable because they provide a more practical approach
oward synergistic beneﬁcial effects of nutrient combinations,
educed portion sizes and caloric content, more satiety, and
isplacement of other foods or beverages.58 The Mediter-
anean diet which is rich in olive oil, nuts, fruits, vegetables,
sh, legumes, dairy products, and wine, is an example of
ood-oriented nutritional recommendation. In a recent ran-
omized crossover trial, theMediterraneandietwas compared
ith a low-fat/high-CHO diet for 6 weeks in 12 biopsy-proven
atients with NAFLD. The results clearly showed a signiﬁcant
eduction in hepatic steatosis (39% vs. 7% assessed by MRS)
nd insulin resistance.59 TheMediterraneandiet has also been
emonstrated to reduce T2DM risk, CVD, cancer, and all-cause
ortality.60 A summaryof recommendations and speciﬁc food
roups that should be promoted in patients with NAFLD, is
rovided in Table 1.
. SummaryAFLD is the most prevalent chronic liver disease in many
ountries. Pharmacologic interventions are few, with low efﬁ-
acy and high potential adverse effects, and obesity has anintimate associationwith hepatic steatosis; therefore, lifestyle
intervention should be considered as a centerpiece of therapy.
The usual steps for the management of NAFLD are gradual
weight reduction and increased physical activity which ame-
liorate the disease in different aspects.
Recent studies have presented clear evidence for weight-
independent effects of diets, rich inMUFAand PUFAand low in
CHO, particularly fructose, on steatosis, liver tests, and insulin
resistance. Given that NAFLD is the hepatic manifestation of a
systemicmetabolic disturbance, interventions should address
four major associated complications: liver disease progres-
sion, diabetesmellitus and its complications, CVD, and cancer;
interventions such as the Mediterranean diet, reduction of
high-GI foods, trans Fas, and saturated fat consumptionwhich
could reduce development of T2DM and CVD. On the whole, it
is recommended to consider these speciﬁc recommendations
in NAFLD therapy even in the absence of deﬁnitive histology-
based supportive evidence (see Table 1). To conclude, whether
speciﬁc nutrient interventions are effective on liver histology
or nutritional supplements could be beneﬁcial, needs further
research.
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